In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer's disease

Jamie Toombs; Henrik Zetterberg

doi:10.1093/braincomms/fcaa054

In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer's disease

Brain Commun. 2020 Jul 2;2(1):fcaa054. doi: 10.1093/braincomms/fcaa054. eCollection 2020.

Authors

Jamie Toombs¹, Henrik Zetterberg^{2

3

4

5}

Affiliations

¹ Centre for Discovery Brain Sciences, UK Dementia Research Institute, The University of Edinburgh, UK.
² UK Dementia Research Institute at UCL, London, UK.
³ Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
⁴ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
⁵ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Abstract

This scientific commentary refers to 'Plasma total-tau, neurofilament light chain and amyloid-β levels and risk of dementia: a population-based study' by de Wolf et al. (https://doi.org/10.1093/brain/awaa054), and 'Relationship of amyloid-b1-42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study' by Lopez et al. (https://doi.org/10.1093/braincomms/fcz038), two papers that illustrate these latest developments.

Publication types

Comment

Grants and funding

681181/ERC_/European Research Council/International